Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Phase II study of weekly carboplatin in pretreated adult malignant gliomas.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Mariantonia C, Casini B, Metro G, Maschio M, Tatiana K, Cognetti F, Fabi A.

J Neurooncol. 2019 Aug;144(1):211-216. doi: 10.1007/s11060-019-03223-x. Epub 2019 Jul 4. Erratum in: J Neurooncol. 2019 Sep 9;:.

PMID:
31273578
2.

A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA.

J Neurooncol. 2006 Jul;78(3):311-6. Epub 2006 May 19.

PMID:
16710748
3.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

4.

Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study.

Roci E, Cakani B, Brace G, Bushati T, Rroji A, Petrela M, Kaloshi G.

Med Arch. 2014;68(2):140-3.

5.

Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma.

Tonder M, Weller M, Eisele G, Roth P.

Chemotherapy. 2014;60(5-6):375-8. doi: 10.1159/000440678. Epub 2015 Oct 24.

6.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.

Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25481791
7.

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G; CABARET/COGNO investigators, Rosenthal MA.

Neuro Oncol. 2015 Nov;17(11):1504-13. doi: 10.1093/neuonc/nov104. Epub 2015 Jun 30.

8.

A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas.

Allen J, Siffert J, Donahue B, Nirenberg A, Jakacki R, Robertson P, DaRosso R, Thoron L, Rosovsky M, Pinto R.

Cancer. 1999 Sep 15;86(6):1064-9.

PMID:
10491535
9.

A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.

Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malec MK.

J Neurooncol. 1994;19(1):69-74.

PMID:
7815106
10.

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA.

Invest New Drugs. 2005 Oct;23(5):495-503.

PMID:
16133802
11.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

12.

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.

Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.

13.

Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):609-30. doi: 10.1007/s11060-015-1910-2. Epub 2015 Nov 3. Review.

PMID:
26530264
14.

[HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood--an interim report].

Gnekow AK, Kaatsch P, Kortmann R, Wiestler OD.

Klin Padiatr. 2000 Jul-Aug;212(4):177-84. German.

PMID:
10994547
15.

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

Burris H 3rd, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J.

J Clin Oncol. 2004 May 1;22(9):1621-9.

PMID:
15117984
16.
17.

A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.

Friedland DM, Dakhil S, Hollen C, Gregurich MA, Asmar L.

Cancer Invest. 2004;22(3):374-82.

PMID:
15493358
18.

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.

Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):58-66.

PMID:
12007942
19.

Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas.

Yaman E, Buyukberber S, Uner A, Coskun U, Yamac D, Ozturk B, Kaya AO, Yildiz R, Benekli M; Anatolian Society of Medical Oncology (ASMO).

Tumori. 2008 Sep-Oct;94(5):674-80.

PMID:
19112939
20.

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M.

Jpn J Clin Oncol. 2012 Oct;42(10):887-95. Epub 2012 Jul 27.

Supplemental Content

Support Center